When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRTX - BeiGene reports preliminary data on tislelizumab+sitravatinib at ESMO I-O 2019
Mirati Therapeutics Inc.
BeiGene (NASDAQ:BGNE) and Mirati Therapeutics (NASDAQ:MRTX) announces preliminary data from an ongoing Phase 1b trial of anti-PD-1 antibody tislelizumab in combination with tyrosine kinase inhibitor sitravatinib in patients with platinum-resistant ovarian cancer.
More news on: BeiGene, Ltd., Mirati Therapeutics, Inc., Healthcare stocks news,